Fig. 2

CLDN6 exerts an inhibitory effect on de novo fatty acid synthesis by downregulating SREBP1 expression. A, B The effect of CLDN6 overexpression on SREBP1, FASN, ACC1, and SCD1 expression at mRNA and protein levels in BC cells (n = 3). C Visualization of the expression levels of CLDN6 and SREBP1 in xenograft tumor tissues. Scale bar, 20 μm. D-E The effect of SREBP1 overexpression on key lipogenic enzymes expression at mRNA and protein levels in CLDN6-overexpressing BC cells (n = 3). F–H The impact of SREBP1 overexpression on palmitic acid, triglyceride and neutral lipid in BC cells with CLDN6 overexpression (n = 3). Scale bar, 50 μm. I–K The impact of SREBP1 overexpression on cell viability (I), clonogenicity (J), and cell cycle progression (K) of BC cells with CLDN6 overexpression. L, M The SREBP1 overexpression-induced alterations in cellular migratory (L) and invasive (M) capacity of BC cells with CLDN6 overexpression (n = 3). Scale bar, 200 μm (L) and 50 μm (M). *P < 0.05, **P < 0.01, ***P < 0.001 denoted the presence of statistically significant disparities